The global left atrial appendage closure devices market accounted for USD 1.53 billion in 2023 and is expected to reach USD 12.15 billion by 2034 with a CAGR of 20.71% during the forecast period 2024-2034. The market will grow due to the rising prevalence of atrial fibrillation, increasing demand for minimally invasive procedures, technological advancements in LAA closure devices increased awareness and acceptance of LAA Closure and favourable reimbursement policies.
Advances in device technology have created next-generation LAAC devices that are safer, more effective, and easier to use. These technological breakthroughs include improvements to device design, materials, delivery systems, and imaging techniques, making LAAC operations safer and more accessible to a larger patient population. For instance, Boston Scientific announced in January 2023 that it had completed the acquisition of Baylis Medical Company Inc.'s electrophysiology portfolio, which includes the LARIAT Suture Delivery Device.
By technique, the endocardial segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 owing to the increasing adoption of advanced endocardial closure devices and their effectiveness in reducing stroke risk in atrial fibrillation patients. For instance, in December 2023, Abbott announced that its Amplatzer Amulet Left Atrial Appendage Occluder had been approved by the FDA to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Additionally, the epicardial segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for alternative approaches in patients with challenging anatomies and the development of innovative epicardial closure device technologies.
By procedure, the percutaneous segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for minimally invasive procedures, advancements in percutaneous device technology, and expanding adoption in a broader patient population. For instance, Abbott announced in April 2022 that its AmplatzerTM Steerable Delivery Sheath is now available in the United States for the treatment of atrial fibrillation. This device works with the company's Amplatzer Amulet TM Left Atrial Appendage Occluder.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 owing to the growing prevalence of atrial fibrillation, increased procedural volumes, and a higher concentration of specialized healthcare facilities offering LAAC procedures. For instance, in December 2023, the FDA approved Abbott's AMPLATZERTM AmuletTM Left Atrial Appendage Occluder. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards outpatient procedures, advancements in minimally invasive techniques, and increased focus on cost-effective healthcare delivery models.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of atrial fibrillation, robust healthcare infrastructure, increasing adoption of advanced medical technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing older population, rising healthcare costs, growing healthcare infrastructure, and increased awareness of atrial fibrillation and stroke prevention. For instance, in May 2023, Biosense Webster's THERMOCOOL SMARTTOUCH® SF Catheter was approved by the FDA to treat atrial fibrillation.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Advances in device technology have created next-generation LAAC devices that are safer, more effective, and easier to use. These technological breakthroughs include improvements to device design, materials, delivery systems, and imaging techniques, making LAAC operations safer and more accessible to a larger patient population. For instance, Boston Scientific announced in January 2023 that it had completed the acquisition of Baylis Medical Company Inc.'s electrophysiology portfolio, which includes the LARIAT Suture Delivery Device.
By technique, the endocardial segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 owing to the increasing adoption of advanced endocardial closure devices and their effectiveness in reducing stroke risk in atrial fibrillation patients. For instance, in December 2023, Abbott announced that its Amplatzer Amulet Left Atrial Appendage Occluder had been approved by the FDA to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Additionally, the epicardial segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for alternative approaches in patients with challenging anatomies and the development of innovative epicardial closure device technologies.
By procedure, the percutaneous segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for minimally invasive procedures, advancements in percutaneous device technology, and expanding adoption in a broader patient population. For instance, Abbott announced in April 2022 that its AmplatzerTM Steerable Delivery Sheath is now available in the United States for the treatment of atrial fibrillation. This device works with the company's Amplatzer Amulet TM Left Atrial Appendage Occluder.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global left atrial appendage closure devices market in 2023 owing to the growing prevalence of atrial fibrillation, increased procedural volumes, and a higher concentration of specialized healthcare facilities offering LAAC procedures. For instance, in December 2023, the FDA approved Abbott's AMPLATZERTM AmuletTM Left Atrial Appendage Occluder. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards outpatient procedures, advancements in minimally invasive techniques, and increased focus on cost-effective healthcare delivery models.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of atrial fibrillation, robust healthcare infrastructure, increasing adoption of advanced medical technologies, and favorable reimbursement policies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the growing older population, rising healthcare costs, growing healthcare infrastructure, and increased awareness of atrial fibrillation and stroke prevention. For instance, in May 2023, Biosense Webster's THERMOCOOL SMARTTOUCH® SF Catheter was approved by the FDA to treat atrial fibrillation.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Technique, Procedure, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Left Atrial Appendage Closure Devices Market Report 2023 - 2034
Left Atrial Appendage Closure Devices Market Analysis & Forecast by Technique 2023 - 2034 (Revenue USD Bn)
- Epicardial
- Endocardial
Left Atrial Appendage Closure Devices Market Analysis & Forecast by Procedure 2023 - 2034 (Revenue USD Bn)
- Percutaneous
- Surgical
Left Atrial Appendage Closure Devices Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Ambulatory Surgical Centers
- Others
Left Atrial Appendage Closure Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Left Atrial Appendage Closure Devices Market: Technique Estimates & Trend Analysis
8. Left Atrial Appendage Closure Devices Market: Procedure Estimates & Trend Analysis
9. Left Atrial Appendage Closure Devices Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Left Atrial Appendage Closure Devices Market
12. Europe Global Left Atrial Appendage Closure Devices Market
13. Asia Pacific Global Left Atrial Appendage Closure Devices Market
14. Latin America Global Left Atrial Appendage Closure Devices Market
15. MEA Global Left Atrial Appendage Closure Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Abbott Laboratories
- Johnson & Johnson (Biosense Webster)
- AtriCure Inc.
- St. Jude Medical (acquired by Abbott)
- CardioFocus Inc.
- Occlutech
- Lifetech Scientific Corporation
- Articure
- SentreHEART Inc.
- Coherex Medical (acquired by Johnson & Johnson)
- Aegis Medical Innovations Inc.
- Left Medical Corporation
- Carag AG
- Lepu Medical Technology (Beijing) Co. Ltd.
